insights_auto
Nega KYNB tushdi 4,12%?
Batafsil oʻrganishchevron_right
KYNB:NASDAQ
Kyntra Bio Inc
6,05 US$
arrow_downward
-4,12%(-0,26) 1K
5-okt, 12:03:16 (GMT-4) · USD
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoKYNB tikeri uchun statistika yaratilmoqda...
Ochish
6,36 US$
Yuqori
6,45 US$
Past
5,62 US$
Bozor kapitali
24,50 mln
Oʻrtacha hajm
25,29 ming
Hajmi
73,96 ming
P/E koeffitsiyenti
0,13
52 haftalik eng yuqori
9,70 US$
52 haftalik eng past
5,62 US$
Aksiya boʻyicha daromad
45,30 US$
Beta
1,05
Muomaladagi aksiyalar
4,05 mln
Xodimlar soni
34
Ochish
6,36 US$
Yuqori
6,45 US$
Past
5,62 US$
Bozor kapitali
24,50 mln
Oʻrtacha hajm
25,29 ming
Hajmi
73,96 ming
P/E koeffitsiyenti
0,13
52 haftalik eng yuqori
9,70 US$
52 haftalik eng past
5,62 US$
Aksiya boʻyicha daromad
45,30 US$
Beta
1,05
Muomaladagi aksiyalar
4,05 mln
Xodimlar soni
34
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
AD HOC NEWS
·
6 soat oldin
Kyntra Bio appoints Singer and Kyntra Bio stock matches EUR 5.63 prior close
Profil
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
Kyntra Bio Inc haqida
CEO-
Xodimlar soni34
Asos solingan1-yan, 1993
Bosh ofislarSan Fransisko, Kaliforniya, Amerika Qo‘shma Shtatlari
Sektor-
Veb-saytkyntrabio.com